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INTRODUCTION. Hepatocellular carcinoma (HCC) is a heterogeneous malignant tumor, often diagnosed at an advanced stage, with a poor prognosis, as well as the sixth world cancer cause of death. For the 
treatment of HCC in advanced unresectable stage, the FDA (Food and Drug Administration) approved the drug Sorafenib (Nexavar®). It is a multikinase inhibitor that may excert its antitumor activity on a multi-omics 
scale. Among the effects induced by sorafenib there have been observed variations in global mRNA and protein expression as well as dysregulation of ncRNAs. To better understand sorafenib-related molecular 
mechanisms, we profiled the expression of a panel of ncRNAs in a sorafenib-treated HCC cell line. Among the most modulated ncRNAs, we observed the dysregulation of the lncRNAs GAS5, HOTTIP and HOXA-
AS2 and the miR-126-3p in different in vitro cancer cell models of HCC, renal (RCC) and breast carcinoma (BC).    
CONCLUSIONS. Over the last decades efforts have been carried out to make 
sorafenib a more effective drug in the management of different solid tumors as 
well as to identify novel molecular biomarkers of response. It is the first line-
treatment for the management of unreseactable HCC and a therapeutic option for 
advanced RCC. Promising results are also emerging on the efficacy of sorafenib in 
combination with gemcitabine and/or capecitabine in BC clinical trials. This study 
highlighted the capability of sorafenib to modulate the expression of a wide range 
of ncRNAs. Specifically, GAS5 and miR-126-3p were involved in the response to 
sorafenib of different cancer cell types. Indeed they could be considered as useful 
and good diagnostic biomarkers of HCC in liquid biopsies.  
Table 1. Differential expression levels of lncRNAs in sorafenib-treated 
HA22T/VGH cells vs untreated with 0.1% DMSO. 
Gene symbol Fold Change * Regulation p-value 
BCYRN1 0.08 DOWN 0.005632 
BDNF-AS 0.45 DOWN 0.022118 
BOK-AS1 0.46 DOWN 0.043302 
CDKN2B-AS1 0.24 DOWN 0.003393 
DISC2 0.25 DOWN 0.008117 
FAS-AS1 1.57 UP 0.008938 
FTX 0.11 DOWN 0.004019 
GAS5 2.69 UP 0.008294 
GNAS-AS1 0.43 DOWN 0.015903 
HEIH 2.16 UP 0.024813 
HOTAIR 0.66 DOWN 0.049147 
HOTTIP 0.28 DOWN 0.000035 
HOXA11-AS 0.43 DOWN 0.012825 
HOXA-AS2 0.09 DOWN 0.018223 
IPW 0.60 DOWN 0.049269 
LUCAT1 0.29 DOWN 0.045304 
NEAT1 0.23 DOWN 0.009658 
NRON 0.24 DOWN 0.013959 
OIP5-AS1 0.38 DOWN 0.010743 
PCAT1 0.15 DOWN 0.043572 
TERC 0.43 DOWN 0.006213 
TMEM161B-AS1 0.20 DOWN 0.004161 
TUG1 0.24 DOWN 0.001951 
* Sorafenib-treated cells vs Untreated 
Table 2. Differential expression levels of miRNAs in sorafenib-treated 
HA22T/VGH cells vs untreated with 0.1% DMSO.  
miR- Fold  Change *  Regulation p-value 
hsa-miR-126-3p 0.44 DOWN 0.021598 
hsa-miR-148a-3p 0.75 DOWN 0.030670 
hsa-miR-16-5p 0.82 DOWN 0.049102 
hsa-miR-27b-3p 0.86 DOWN 0.015058 
hsa-miR-3183 3.35 UP 0.002017 
hsa-miR-3907 2.87 UP 0.022169 
hsa-miR-4454 0.89 DOWN 0.039167 
hsa-miR-4516 2.43 UP 0.029799 
HOXA-AS2 expression. The steady-state expression levels HOXA-AS2 
(H) was measured by qPCR in all 8 cell lines (3 HCC, 3 RCC and 2 BC) 
treated and untreated with 15 μM Sorafenib. HOXA-AS2 expression 
levels were down in hepatocellular (I), renal (J) and breast (K) cells 
exposed to sorafenib when compared with cells exposed to DMSO. The 
histograms represent the mean values of 3 experiments, bars are ± SEM. 
Unpaired t-test; *p<0.05, **p<0.01, ***p<0.001. 
* Sorafenib-treated cells vs Untreated 
Experimental workflow. We employed the RT2 lncRNA PCR Array 
Human lncFinder (Qiagen) and miScript miRNA PCR Array Human 
Liver miFinder (Qiagen) to analyze the expression profile of 84 different 
disease- or pathway- focused lncRNAs and miRNAs in HCC cell line 
(HA22T/VGH) treated and untreated with 15 μM sorafenib for 24 hours. 
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Expression levels of miR-126-3p and GAS5 in solid biopsies. The expression 
levels of GAS5 and miR-126-3p were measured by qPCR in 25 HCC solid 
biopsies and their corresponding peritumoral counterpart (PT). miR-126-3p levels 
were significantly down-modulated in HCC compared to PT. On the other hand 
GAS5 levels showed a trend of up-regulation in HCC compared to PT. Two-tailed, 
paired t-test; *p<0.05, **p<0.01, ***p<0.001. 
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Plasma circulating  levels of miR-126-3p. The expression levels of miR-126-3p 
were measured by qPCR in 25 plasma of healthy subjects and HCC patients. HCC 
patients plasma showed higher levels of miR-126-3p compared to healthy controls 
(T). ROC curve analysis of plasma miR-126-3p (U). AUC: area under the ROC 
curve; CI: confidence interval. Two-tailed, unpaired t-test; *p<0.05, **P<0.01, 
*** p<0.001. 
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Dysregulated lncRNA. 23 lncRNAs resulted significantly dysregulated 
in sorafenib-treated HA22T/VGH cells compared to cells treated with 
DMSO. In particular, 3 lncRNAs were up-regulated while 20 were 
down-regulated. 
Dysregulated miRNA. 8 miRNAs resulted significantly dysregulated in 
sorafenib-treated HA22T/VGH cells compared to cells treated with 
DMSO. In particular, 3 were up-regulated and 5 down-modulated. 
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GAS5 expression. The steady-state expression levels of GAS5 (A), 
were measured by qPCR in 8 cell lines (3 HCC, 3 RCC and 2 BC) 
treated and untreated with 15 μM Sorafenib. GAS5 was up-regulated in 
all HCC cell lines except of SKHp1C3 (B), and in all renal cells (C) and 
in all breast (D) cancer cells treated. The histograms represent the mean 
values of 3 experiments, bars are ± SEM. Unpaired t-test; *p<0.05, 
**p<0.01, ***p<0.001; ****p<0.0001.  
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HOTTIP expression. The steady-state expression levels of HOTTIP 
(E) was measured by qPCR in all cell lines (3 HCC, 3 RCC and 2 BC) 
treated and untreated with 15 μM Sorafenib. HOTTIP resulted down-
modulated in either HCC (F) and RCC (G) cells treated with 15 μM 
sorafenib. The histograms represent the mean values of 3 experiments, 
bars are ± SEM. Unpaired t-test; *p<0.05, **p<0.01, ***p<0.001; 
****p<0.0001.  
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miR-126-3p expression. The steady-state expression levels of miR-
126-3p (L) was measured by qPCR in all cell lines (3 HCC, 3 RCC and 
2 BC) treated and untreated with 15 μM Sorafenib. miR-126-3p was 
down-modulated following sorafenib  treatment in all the cancer cell 
lines used except of Caki-1 where it was up-regulated (M-O). The 
histograms represent the mean values of 3 experiments, bars are ± SEM. 
Unpaired t-test; *p<0.05, **p<0.01, ***p<0.001. 
Plasma circulating levels of GAS5. The expression levels of GAS5 were 
measured by qPCR in 25 plasma of healthy subjects and HCC patients. HCC 
patients plasma showed significantly lower levels of GAS5 compared to healthy 
control (R). ROC curve analysis of plasma GAS5 (S). AUC: area under the ROC 
curve; CI: confidence interval. Two-tailed, unpaired t-test; *p<0.05, **P<0.01, 
*** p<0.001. 
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